March 25 (Reuters) - Merck & Co Inc MRK.N:
MERCK & CO- SEES TO RECORD PRE-TAX CHARGE OF $200 MILLION, OR ABOUT $0.06 PER SHARE, TO BE INCLUDED IN GAAP AND NON-GAAP RESULTS IN QUARTER DEAL CLOSES
MERCK ENTERS EXCLUSIVE LICENSE AGREEMENT FOR HRS-5346, AN INVESTIGATIONAL ORAL LIPOPROTEIN$(A)$ INHIBITOR, FOR CARDIOVASCULAR DISEASE FROM JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
MERCK & CO INC - HENGRUI PHARMA TO RECEIVE $200 MILLION UPFRONT PAYMENT FROM MERCK
MERCK & CO INC - HENGRUI PHARMA ELIGIBLE FOR UP TO $1.77 BILLION IN MILESTONE PAYMENTS
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.